Maat Desnuda Galería de Fotos y Vídeos

MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology

MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe

Maat Pharma SA MAAT

MaaT Pharma, Leader in Development of Microbiome-Based Therapies in Oncology, Awarded Government Funding for Clinical Development of MaaT033 as part of the France 2030 Plan

MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026

Lisbon’s MAAT Museum Heralds New Era for Contemporary Art in Portugal

Zindagi Gulzar Hai to end: What the replacement show ‘Maat’ is all about

Maat (Atenolol) Drug Price and Information

MaaT Pharma to Hold Annual General Meeting on June 16, 2026

MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress

Is MaaT back? After 18 months on hold, microbiome biotech sees end to impasse with FDA

MaaT, eyeing 2026 launch for microbiome therapy, posts 18-month data in aGvHD

MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management

MaaT microbiota drug shows survival advantage in GvHD

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

AACR 2025: MaaT Pharma, the gut microbiome, and immuno-oncology

Availability of MaaT Pharma’s 2024 Universal Registration Document (URD)